Thomas X. Neenan

Chief Business Officer and Consultant to Biocon
Dr. Neenan has 20 years of drug discovery, development and business experience with extensive experience in the transition of pharmaceutical projects from academia to industry.  Prior to Biocon, Dr. Neenan was the Founder and CTO of Sideris Pharmaceuticals, a clinical stage developer of small molecules for the treatment of disease of iron overload, with technology licensed from the University of Florida.   Dr. Neenan founded the company in 2012, raised $32M in equity financing and completed an option agreement with Novartis to acquire to the company following Phase 2 studies.

Prior to Sideris, Dr. Neenan served as Founder and CEO of Viscus Biologics in Cleveland Ohio, and he has held numerous senior management roles in the biotech industry, including at Proxy Biomedical (Galway, Ireland), Warwick Effect Polymers (Coventry, UK) and Trine Pharmaceuticals (Waltham, MA).  He was Vice-President, Business Operations for Genzyme Drug Discovery and Development and is currently on the boards of Sun BioPharma Inc., a Minneapolis-based pancreatic oncology company, and Neomics, Seoul, Korea.  He received his Ph.D. in chemistry from Pennsylvania State University, and was a Fellow at Harvard University.